Navigation Links
Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection

BEDFORD, Ohio, Jan. 14 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce FDA approval for the addition of 100 mg/50 mL Fluconazole Injection to its existing Fluconazole Injection line. This product is AP rated and is equivalent to Diflucan® by Pfizer. Fluconazole Injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated for the prophylaxis of candidiasis.

(Logo: )

"Pharmacists asked, we answered. In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to be the first to offer this unique dosage. Fluconazole Injection 100 mg/50 mL is right-sized for smaller doses, speeding productivity and saving time. This continues to demonstrate our commitment to providing a broad-based portfolio of products," said David Gaugh, Vice President of Bedford Laboratories.

Bedford Laboratories will supply Fluconazole Injection sterile iso-osmotic solution containing 2 mg/mL of fluconazole in glass vials in the following presentations:  Vials containing either 100 mg, 200 mg or 400 mg equivalent of fluconazole. In addition, Bedford Laboratories will supply Fluconazole Injection as a sterile iso-osmotic solution containing 2 mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations:  200 mg/100 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400 mg/200 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site,

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.

Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. BVL has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people.  For more information on Ben Venue Laboratories and current career opportunities, visit

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit

Diflucan® is a registered trademark of Pfizer Inc.

SOURCE Bedford Laboratories



SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
8. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
11. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Post Your Comments:
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
Breaking Medicine News(10 mins):